These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27058207)

  • 41. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
    Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
    Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
    World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiomics for predicting MGMT status in cerebral glioblastoma: comparison of different MRI sequences.
    Zheng F; Zhang L; Chen H; Zang Y; Chen X; Li Y
    J Radiat Res; 2024 May; 65(3):350-359. PubMed ID: 38650477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
    Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
    Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
    Lobanova NV; Shishkina LV; Ryzhova MV; Kobyakov GL; Sycheva RV; Burov SA; Lukyanov AV; Omarova ZR
    Arkh Patol; 2016; 78(4):10-19. PubMed ID: 27600777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of
    Kim M; Yoo J; Chang JH; Kim SH
    Anticancer Res; 2022 Jan; 42(1):335-341. PubMed ID: 34969742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
    Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
    Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
    J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
    Takeuchi S; Wada K; Toyooka T; Shinomiya N; Shimazaki H; Nakanishi K; Nagatani K; Otani N; Osada H; Uozumi Y; Matsuo H; Nawashiro H
    Neurosurgery; 2013 Jan; 72(1):33-41; discussion 41. PubMed ID: 23096413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
    Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
    J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Automatic estimation of extent of resection and residual tumor volume of patients with glioblastoma.
    Meier R; Porz N; Knecht U; Loosli T; Schucht P; Beck J; Slotboom J; Wiest R; Reyes M
    J Neurosurg; 2017 Oct; 127(4):798-806. PubMed ID: 28059651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
    Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
    J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive markers for MGMT promoter methylation in glioblastomas.
    Kanazawa T; Minami Y; Jinzaki M; Toda M; Yoshida K; Sasaki H
    Neurosurg Rev; 2019 Dec; 42(4):867-876. PubMed ID: 30673883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.